Related Experiment Video
Updated: Aug 15, 2026
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Impact of bacterial pneumonias on world child health
1Wellcome Trust Research Laboratories, Centre for Geographic Medicine Research - Coast, P.O. Box 230, Kilifi, Kenya. menglish@kilifi.mimcom.net
Insights
Lower respiratory infections cause millions of deaths annually, primarily in young children. While vaccines exist, cost limits access, making case management crucial for bacterial pneumonia, despite emerging threats like antibiotic resistance.
Area of Science:
- Global Health
- Infectious Diseases
- Pediatrics
Background:
- Lower respiratory infections (LRIs) cause approximately 4 million deaths yearly, disproportionately affecting young children in low-income nations.
- Bacterial pneumonias are a significant cause of LRI mortality, though precise estimation is challenging due to diagnostic difficulties.
Purpose of the Study:
- To highlight the global burden of bacterial pneumonias in young children.
- To assess current and future strategies for managing and preventing these infections, considering economic and resistance factors.
Main Methods:
- Review of existing data on LRI mortality and causes.
- Analysis of the impact and accessibility of current interventions, including vaccines and case management.
- Evaluation of emerging threats such as antibiotic resistance and HIV.
Main Results:
- Bacterial pneumonias are a major contributor to LRI deaths, particularly in vulnerable populations.
- Vaccines for key pathogens (H. influenzae type B, S. pneumoniae) are available but costly, limiting their reach.
- Case management remains the primary, cost-effective strategy for bacterial pneumonia, but faces threats.
Conclusions:
- Effective case management is vital for reducing global bacterial pneumonia mortality, especially in resource-limited settings.
- Antibiotic resistance and HIV infection pose significant future risks to current control strategies, potentially increasing mortality and health inequity.
Abstract:
Lower respiratory infections (LRIs) are estimated to cause approximately 4 million deaths each year, the majority in previously healthy young children from low-income countries. Bacterial pneumonias are likely to account for the major proportion of deaths but because accurate diagnosis is difficult, their precise contribution is difficult to estimate. Effective protection against two of the most important pathogens (H. influenzae type B and S. pneumoniae) is now available even for young infants. The high cost of these interventions is however likely to prohibit their use in areas likely to benefit most. Case management which can be effective at reducing mortality and which is relatively cheap at present is likely therefore to remain the principal means of tackling bacterial pneumonias globally. Antibiotic resistance to cheap drugs and possibly HIV infection pose a potentially enormous threat to this strategy with the prospect of an increasing global death toll with an even more inequitable distribution of disease as we begin the new century.
Related Concept Videos
01:29Pneumonia I: Introduction
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia III: Complications and Assessment
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:29Pneumonia II: Pathophysiology
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: